Effect of thiazolidinediones on insulin resistance and cardiovascular risk factors
https://doi.org/10.14341/omet200822-5
Abstract
The development of new, more effective ways of multivariate control of type 2 diabetes is currently the most important problem of endocrinology. This is caused by a high prevalence of this disease in the population, as well as a significant risk of complications leading to early morbidity and mortality of patients. Clinical management of patients with type 2 diabetes should be based on a thorough study of the mechanisms of this disease in order to correct the basic pathogenetic defects.
About the Authors
T Yu Demidova
Russian medical academy of postdegree education, Moscow
E N Erokhina
Russian medical academy of postdegree education, Moscow
References
1. Аметов А.С. Инсулиносекреция и инсулинорезистентность: две стороны одной медали. // Проблемы эндокринологии. - 2002. - Т.48. - № 3. - С.31-36.
2. Аметов А.С. Нарушения жизненного цикла и функции β-клеток поджелудочной железы: центральное звено патогенеза сахарного диабета 2 типа. Учебное пособие. - М., 2002.
3. Дедов И.И., Мельниченко Г.А. Ожирение: этиология, патогенез, клинические аспекты. - М., 2004; 44-84.
4. Clauser E, Leconte I, Auzan C., Molecular basis of Insulin Resistence Hormone Research, 1992,38: 5-12.
5. DeFronzo, R.A Pathogenesis of type 2 diabetes mellitus: a blanked overview. Diabetologia. 1992, vol.35:389-397
6. Carpenter J-L. Insulin-Induced and constitutive internalization of the insulin receptor. Hormone Research, 1992;38:13-18
7. DeFronzo, R.A. The triumvirate: beta-cell, muscle, liver: a collusion respon- sible for NIDDM. Diabetes. 1988, 37:667-687.
8. Boden G. Shulman Gl. Free acids in obesity and type 2 diabetes: defining their rile in the development of insulin resistence and β-cell dysfunction. Eur J Clin Invest. 2002;32(suppl.3):14-9.Howard B.V. Howard W.J. Dyslipidemia in non-insulin-dependent diabetes mellitus Endocrine reviews 1994; vol.15, № 3: 263-274.
9. Nathan D.M., Buse J.B., Davidson M.B., Heine R.J., Holman R.R., Sherwin R., and Zinman B. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy; Diabetes Care 2006; 49: 1711-21.
10. Forman LM, Simmons DA, Diamond RH. Hepatic failure in a patient taking rosigli- tazone. Ann Intern Med. 2000;132:118-121.
11. Arny l. Werner,M.T. Travaglini. A Review of rosiglitazone in type 2 diabetes Mellitus. Pharmacotherapy. Pharmacotherapy Publications 2001,21(9):1082- 1099. Diamant M, Heine RJ Thiazolidindionediones in type2 diabetes mellitus:cur- rent clinical evidence Drugs 2003;63:1373-1405.
12. Ovalle F, Bell DS. Clinical evidence of thiazolidindionediones -induced improve- ment of pancreatic cell function in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2002;4: 56-59.
13. Fonseca VA Biswas N Salzman A Once-daily rosiglitazone in combination with met- formin effectively reduced hyperglycemia in patients with type 2 diabetes. Diabetes 1999 ;48: A100.
14. SecreeR,ShawJ,ZimmetP.Diabetes and impaired glucose tolerance:prevalence and projection Diabetes atlas,2nd end Brussels: International Diabetes Federation,2003:17-71
15. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glu- cose tolerance or impaired fasting glucose: a randomized controlled trial www.the- lancet.com(published online September 15,2006)
Review
For citations:
Demidova T.Yu., Erokhina E.N. Effect of thiazolidinediones on insulin resistance and cardiovascular risk factors. Obesity and metabolism. 2008;5(2):2-5. (In Russ.) https://doi.org/10.14341/omet200822-5
Views:
377
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
